Straits Times Index
3,264.53 -35.51 (-1.08%) Nikkei
38,267.18 +64.81 (+0.17%) Hang Seng
18,313.86 -165.51 (-0.90%) FTSE 100
8,354.05 +40.38 (+0.49%) Bitcoin USD
61,409.02 -1,204.48 (-1.92%) CMC Crypto 200
1,308.33 +13.66 (+1.06%)
Eli Lilly and Company (LILY34.SA)
| Previous close | 131.56 |
| Open | 0.00 |
| Bid | 131.50 x 0 |
| Ask | 132.93 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 13,833 |
| Market cap | 3.776T |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 116.10 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.60 (0.46%) |
| Ex-dividend date | 14 Feb 2024 |
| 1y target est | N/A |
- PR Newswire
Lilly Declares Second-Quarter 2024 Dividend
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2024 of $1.30 per share on outstanding common stock.
- PR Newswire
Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum
Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first quarter of 2024.
- PR Newswire
Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
Eli Lilly and Company (NYSE: LLY) today announced positive topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints. Percentage change in AHI was a key secondary endpoint in both studies. AHI records the number of times a person's breathing shows a restricted or complete block of airflow per hour of sleep and is used to evaluate the sever
